stoxline Quote Chart Rank Option Currency Glossary
  
Regulus Therapeutics Inc. (RGLS)
8.16  0 (0%)    06-25 16:00
Open: 8.16
High: 8.16
Volume: 8,756,394
  
Pre. Close: 8.16
Low: 8.16
Market Cap: 565(M)
Technical analysis
2025-07-11 4:51:00 PM
Short term     
Mid term     
Targets 6-month :  9.74 1-year :  11.38
Resists First :  8.34 Second :  9.74
Pivot price 8.15
Supports First :  7.97 Second :  7.75
MAs MA(5) :  8.1 MA(20) :  8.1
MA(100) :  4.15 MA(250) :  2.59
MACD MACD :  0.3 Signal :  0.4
%K %D K(14,3) :  68.9 D(3) :  62.9
RSI RSI(14): 66.6
52-week High :  8.34 Low :  0.83
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ RGLS ] has closed below upper band by 49.8%. Bollinger Bands are 75.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 25 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.17 - 8.2 8.2 - 8.24
Low: 8.06 - 8.1 8.1 - 8.15
Close: 8.09 - 8.16 8.16 - 8.22
Company Description

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Headline News

Wed, 02 Jul 2025
Regulus Therapeutics to be Acquired by Novartis - TipRanks

Wed, 25 Jun 2025
Novartis completes acquisition of Regulus Therapeutics and initiates Nasdaq delisting - Investing.com

Wed, 04 Jun 2025
Regulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 Payout (NASDAQ:RGLS) - Seeking Alpha

Thu, 08 May 2025
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - PR Newswire

Sun, 04 May 2025
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS - Business Wire

Wed, 30 Apr 2025
Novartis to Buy Regulus Therapeutics for as Much as $1.7 Billion (NVS, RGLS) - Bloomberg

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 69 (M)
Shares Float 58 (M)
Held by Insiders 2.7 (%)
Held by Institutions 82.8 (%)
Shares Short 1,760 (K)
Shares Short P.Month 1,910 (K)
Stock Financials
EPS -0.69
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.03
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -34.3 %
Return on Equity (ttm) -53.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) -0.53
Sales Per Share 0
EBITDA (p.s.) -0.75
Qtrly Earnings Growth 0 %
Operating Cash Flow -44 (M)
Levered Free Cash Flow -26 (M)
Stock Valuations
PE Ratio -12
PEG Ratio 0
Price to Book value 7.84
Price to Sales 0
Price to Cash Flow -12.98
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android